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Abstract
Background: While a number of studies have examined miRNA profiles across the molecular subtypes of breast
cancer, it is unclear whether BRCA1 basal-like cancers have a specific miRNA profile. This study aims to compare
grade independent miRNA expression in luminal cancers, sporadic and BRCA1 basal-type breast cancers. It also aims
to ascertain an immunohistochemical profile regulated by BRCA1 specific miRNAs for potential diagnostic use.
Methods: miRNA expression was assessed in 11 BRCA1 basal, 16 sporadic basal, 17 luminal grade 3 cancers via
microarrays. The expression of Cyclin D1, FOXP1, FIH-1, pan-ERβ, NRP1 and CD99, predicted to be regulated by
BRCA1 specific miRNAs by computer prediction algorithms, was assessed via immunohistochemistry in a cohort of
35 BRCA1 and 52 sporadic basal-like cancers. Assessment of cyclin D1, FOXP1, NRP1 and CD99 expression was repeated
on a validation cohort of 82 BRCA1 and 65 sporadic basal-like breast cancers.
Results: Unsupervised clustering of basal cancers resulted in a “sporadic” cluster of 11 cancers, and a “BRCA1” cluster
of 16 cancers, including a subgroup composed entirely of 10 BRCA1 cancers. Compared with sporadic basal cancers,
BRCA1 cancers showed reduced positivity for proteins predicted to be regulated by miRNAs: FOXP1 (6/20[30 %]
vs. 37/49[76 %], p < 0.001), cyclin D1 (8/22[36 %] vs. 30/46[65 %], p = 0.025), NRP1 (2/20[10 %] vs. 23/46[50 %], p = 0.002).
This was confirmed in the validation cohort (all p < 0.001). Negative staining for 2 or more out of FOXP1, cyclin D1 and
NRP1 predicts germline BRCA1 mutation with a sensitivity of 92 %, specificity of 44 %, positive predictive value of 38 %
and a negative predictive value of 94 %.
Conclusion: Sporadic and BRCA1 basal-like cancers have grade independent miRNA expression profiles. Furthermore
miRNA driven differences in the expression of proteins in BRCA1 basal cancers may be detected via immunohistochemistry.
These findings may have important diagnostic implications, as immunohistochemical assessment of basal cancers, in
addition to the patient’s family and clinical history, may potentially identify patients who may benefit from BRCA1 gene
testing.
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Background
Basal-like breast cancers are a subset of breast cancers
characterised by triple negativity for ER, PR and HER2,
and the expression basal/myoepithelial markers such as
CK5/6 [1], CK14 [2] and EGFR [3]. They comprise ap-
proximately 15 % of all breast cancers [1, 4], and are as-
sociated with a more aggressive behaviour and also lack
available targeted therapy. It is estimated that 2 % of all
breast cancers are directly attributable to inherited mu-
tations in the breast cancer susceptibility gene BRCA1
[5]. A strong link exists between BRCA1 mutations and
basal phenotype, with 80–90 % of BRCA1 cancers ex-
pressing this phenotype [6].
microRNAs are small non-coding RNAs of 20–27 nu-
cleotides that suppress translation through imperfect
base pairing with their target mRNAs [7]. It is estimated
that ~20 % of mRNA targeted by miRNAs undergo RISC
mediated cleavage [8], The remainder may undergo
translational silencing without associated changes in
mRNA expression [9–11]. Although a number of studies
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examined miRNA profiles across the molecular subtypes
of breast cancer [12–16], it is unclear whether the basal-
like miRNA profiles obtained were independent of
tumour proliferation and differentiation as defined by
grade. The aim of this study is to: 1) derive a basal type
miRNA signature that is independent of grade, 2) com-
pare miRNA expression between sporadic and BRCA1
basal cancers to derive a BRCA1 basal signature using
formalin fixed paraffin embedded (FFPE) tissue and 3)
interrogate via immunohistochemistry the expression of
proteins, predicted by computer algorithms, to be regu-
lated by BRCA1 basal specific miRNAs. Identification of
a basal type miRNA signature will aid in the targeting of
specific miRNAs for further investigation. This is par-
ticularly important in view of the limited therapeutic op-
tions available for this particularly aggressive variant of
breast cancer. It is has been shown that due to their
fragment length, miRNA integrity does not appear to be
affected storage as archival FFPE tissue [17]. Generation
of a “BRCA1 basal” miRNA and immunohistochemical
profile in FFPE tissue may identify patients with basal
type cancers who will require BRCA1 genetic testing.
Methods
Samples for miRNA analysis
Forty-four primary grade III breast cancer (11 BRCA1
basal, 16 sporadic basal, 17 luminal) and 13 normal
breast FFPE (formalin fixed, paraffin embedded) speci-
mens were collected for the study. Definitions of intrin-
sic subtypes were based on ER, HER2 in situ
hybridization, EGFR and CK5/6 staining, as per Nielson
et al. [3]: Basal cancers (ER negative, HER2 negative,
CK5/6 and/or EGFR positive), Luminal cancers (ER posi-
tive, HER2 negative). Basal cancers from patients with
documented BRCA1 mutations were sourced from
kConFab (www.kconfab.org), whereas normal breast tis-
sue, sporadic basal and luminal cancers were collected
from the Department of Pathology, Peter MacCallum
Cancer Centre and the Victorian Cancer Biobank. Pa-
tients with sporadic basal cancers did not have a signifi-
cant family history as defined by National Cancer
Institute guidelines for BRCA1/BRCA2 mutation testing
(www.cancer.gov). The clinico-pathological characteris-
tics of the patients included in the study are listed in
Additional file 1: Table S1. The study has ethics approval
(Peter MacCallum Cancer Centre 09/36). For patients with
sporadic cancers, due to the use of archival FFPE tissue,
written informed consent was not required by the ethics
committee. For BRCA1 patients, written informed consent
was obtained as per kConFab (Kathleen Cuningham
Foundation Consortium for research into Familial
Breast cancer) biobank guidelines (www.kconfab.org).
Three basal (HS578T, MDA-MB-231, MDA-MB-468, all
with wild-type BRCA1) and two luminal (MDA-MB-453,
MCF-7) breast cancer cell lines were also included in the
study.
RNA extraction
For primary tumours and normal breast tissue, 10 μm
thick sections were cut from FFPE tissue blocks. The
sections were dewaxed in xylene, placed through 100 %
alcohol and allowed to dry. The samples were needle
microdissected to ensure the proportion of tumour (or
normal epithelium) was greater than 80 %, prior to
placement into lysis buffer (Agencourt Formapure kit,
Beckman Coulter, Beverly, MA, USA). Tissue was
digested as per kit protocol (incubate at 70 ° C for 1 h,
then add 20 μl of Proteinase K and incubate at 55 ° C
for 1 h). Total RNA was extracted via a standard TRI-
ZOL(Sigma)/chloroform protocol. For cell lines, total
RNA was extracted using the total RNA protocol from
the mirVana miRNA Isolation Kit (Ambion, TX, USA).
All samples underwent DNase treatment with the
Ambion DNA-free kit (Ambion, TX, USA).
miRNA array
For each sample, 250 ng of total RNA was labelled and hy-
bridized on Human v2 MicroRNA Expression BeadChips
(Illumina, San Diego, CA, USA), according to the manu-
facturers recommendations (Illumina MicroRNA Expres-
sion Profiling Assay Guide). The layout of samples across
the beadchips is shown in Additional file 1: Table S2.
Sixty-nine samples (44 tumour, 13 normal, 7 controls and
5 cell lines) were hybridised on six beadchips across two
separate runs: Run 1 (1 beadchip, 11 samples) and Run 2
(5 beadchips, 58 samples). The sample groups were rando-
mised across the beadchips and also based on position
within the beadchip. Controls were included for compari-
sons between the six beadchips and also between the two
separate runs. The correlation of miRNA from control
samples across the beadchips are outlined in Additional
file 2: Figure S1.
The BeadChips were scanned with the Illumina
iScan Reader. Data were imported into GenomeStudio
(Illumina), from which raw data with background
subtraction were exported to PARTEK Genomics
Suite (St. Louis, Missouri, USA) for further analysis.
Probes with a maximum intensity value of less than
150 units across all samples were excluded. Of the
1145 probes present on the array, 1037 were used for
subsequent analyses. Raw probe intensities were
shifted, such that the minimum probe intensity for
each sample was equal to 1. All values were trans-
formed by taking logs (base 2), followed by quantile
normalisation [18]. Probe mapping for Illumina
MicroRNA Expression v2 BeadChips was based on
miRBase v.12.0.
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Differential expression between groups was assessed
using ANOVA, with inclusion of the Beadchip number
as an independent variable to control for variations be-
tween Beadchips. A p-value of < 0.05, after Benjamini-
Hochberg adjustment for multiple tests, was regarded as
significant.
For each miRNA, the expression profiles were standar-
dised to a mean of zero and a standard deviation of 1
prior to unsupervised hierarchical clustering. Clustering
was performed using average linkage and Pearson cor-
relation [12]. The full array data is available in GEO
(Accession number: GSE61438).
microRNA real time RT-PCR
Expression of microRNA (miRNA)s hsa-miR-374b, −190b,
−198, −892a, −130b*, −218, −590-3p and −149 was assayed
using real time RT-PCR. cDNA was reversed transcribed
from total RNA samples using TaqMan MicroRNA assays
and the TaqMan MicroRNA reverse transcription kit
(Applied Biosystems). The cDNA was amplified using
TaqMan microRNA Assay primers and the TaqMan
Universal PCR Mastermix, according to the manufac-
turer’s instructions on the Roche Lightcycler 480. The
relative miRNA expression levels were calculated by
normalisation with RNU6B expression [19] using the
second derivative (Cp) method [20]. Comparisons be-
tween groups were made using the un-paired t-test and
correlations with array data were investigated using
Pearson correlation on GraphPad Prism 5 (La Jolla,
CA, USA).
Prediction of miRNA targets
Predicted targets of miRNAs were identified via a union
search of the two target prediction algorithms miRBase
and TargetScan 5.1. Analysis of target protein expression
by pSILAC (pulsed stable isotope labelling by amino
acids in cell culture) suggests the specificity of these two
algorithms are 44 and 61 % respectively [21]. Hence to
improve specificity, only genes that are the predicted tar-
gets of three or more miRNAs differentially expressed
between tumour groups was reported.
Ago2 immunoprecipitation studies by Karginov et al.
have shown that approximately 20 % of mRNA targets
undergo miRNA-induced cleavage. For the remainder of
the targets (80 %), protein translation is suppressed
without changes in mRNA levels [21, 22]. To identify
the subset that undergoes miRNA-mediated cleavage,
predicted targets derived from above were cross refer-
enced with gene expression array data.
Gene expression array
Gene expression data for 14 BRCA1 and 10 non-BRCA1
(5 BRCA2 and 5 BRCAX) basal cancers were derived
from a cohort previously described by Waddell et al.
(Data available on GEO, accession number GSE19177)
[23]. RNA was extracted (Qiagen, Doncaster, VIC) from
fresh frozen tissue and gene expression profiling was
performed as per the manufacturer’s guidelines using
450 ng total RNA and Illumina Human-6 version 2
BeadChips containing 46,000 probes (Illumina Inc., San
Diego, CA). Raw data were imported from Illumina
Beadstudio v3.2 to PARTEK for further processing. Data
were normalized with quantile normalisation, then fil-
tered using an Illumina detection score of > 0.95 in at
least one sample, which yielded 24,004 probes that were
used in further analyses.
Immunohistochemistry for miRNA targets
Tissue microarrays (TMAs) with single 1 mm cores
were constructed. Cyclin D1, FOXP1, FIH-1, pan-ERβ,
NRP1 and CD99 immunohistochemistry was performed
on TMAs constructed from a cohort of 35 BRCA1
basal cancers from kConFab, and 52 sporadic basal
cancers from the Instituti Ospitalieri di Cremona, Italy.
Selection of antibodies was based on their previously
described associations with BRCA1 status, wherever
possible [24–28]. Immunohistochemistry for cyclin D1,
FOXP1, NRP1 and CD99 was repeated on a second val-
idation cohort composed of 82 BRCA1 basal cancers
from kConFab, and 65 sporadic basal cancers from the
Peter MacCallum Cancer Centre, Melbourne. TMA
sections were cut from each block at 4 μm thick inter-
vals, dewaxed, and placed through graded alcohol and
placed into water. The antibody clones used and their
titrations are listed in Additional file 1: Table S3. Anti-
gen retrieval, incubation and visualisation for FIH and
pan-ERβ were performed as per previous published
studies [27, 29]. For NRP1 antigen retrieval was per-
formed in a pressure cooker using high pH EnVision
FLEX Target Retrieval Solution (Dako, Glostrup,
Denmark) for 2 min. Antigen-antibody complex was
detected using Envision FLEX system. FOXP1 and cyc-
lin D1 staining was performed on the Ventana Bench-
mark® ULTRA system. Antigen retrieval was performed
using Ventana ULTRA Cell Conditioner 1 and visualized
with Ventana Ultraview Universal DAB. The intensity of
staining was scored as negative = 0; weak staining = 1; mod-
erate staining = 2; or strong staining = 3. The percentage of
tumour cells stained in the given core scored as: 0 % = 0;
1–10 % = 1; 11–50 %= 2; 51–80 % = 3; 81–100 % = 4. The
scores for both staining intensity and the percentage of
positive tumour cells were added together to give a
maximum score of 7. Comparisons between groups
were based on a chi square (based on presence or ab-
sence of staining) and Mann-Whitney U tests (based
on scores out of 7) performed on SPSS 16.0 (SPSS, IL,
USA).
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Results
Unsupervised hierarchical cluster analysis reveal distinct
microRNA signatures among basal and luminal breast
cancers
Unsupervised hierarchical clustering was performed on
all 63 samples, based on the expression of 133 miRNAs.
Selection of miRNAs was based on the top 75 miRNAs
(based on fold change) differentiating between basal and lu-
minal cancers and between BRCA1 and sporadic basal can-
cers (Fig. 1). To take into account the variation in probe
intensity between the two runs (see above), standardisation
for each miRNA to a mean of zero and a standard deviation
of one was carried out separately for each run.
The analysis accurately separated normal tissue from
breast cancer samples. It also separated basal from lu-
minal cancers. There was some overlap (involving a clus-
ter of 4 samples) between normal and luminal cancers.
However it is noted that 3 of these 4 samples (normal
N8, N9, luminal cancer L14), were from the smaller run
of 11 samples. This overlap may be due to differences in
hybridisation between the two different runs, despite an
attempt to correct this by standardising the runs separ-
ately. Basal cell lines had a different miRNA profile com-
pared to other primary basal cancer samples, and closely
resembled the signature for luminal cell lines.
A number of miRNAs correlated with basal phenotype
in the current and previous studies. miRNAs that were
overexpressed in basal cancers across several studies (fol-
lowing adjustment of p values for multiple tests) include
hsa-miR-17/*, 18a/b, 19a, 93, 106a/b, 135b and 142-5p.
Similarly hsa-miR-29c/*, 109b, 342-3p/5p, 375 and hsa-
let-7c were underexpressed in basal cancers (Table 1).
Cluster analysis of basal cancers reveals miRNA signature
enriched for BRCA1 cancers
A cluster analysis based on the top 100 miRNAs discrim-
inating between BRCA1 and sporadic basal cancers was
performed on all basal samples (including cell lines). This
revealed two distinct signatures among the basal breast
cancers (Fig. 2). A “BRCA1” rich cluster of 16 basal can-
cers, which included all 11 BRCA1 basal cancers plus 5
sporadic basal cancers, and a second “sporadic” basal clus-
ter, composed of the remaining 11 sporadic basal cancers.
Within the “BRCA1” cluster there was a subgroup com-
posed entirely of 10 BRCA1 cancers. Basal cell lines, all
with wild-type BRCA1, had a profile more closely resem-
bling sporadic basal cancers rather than basal cancers with
known BRCA1 mutations. miRNAs that are differentially
expressed between BRCA1 and sporadic basal cancers,
with a fold change of > 2.5, are listed in Table 2.
Fig. 1 Unsupervised hierarchical cluster analysis over 133 classifying miRNAs (Pearson correlation, average linkage), all 62 samples
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In order to assess the specificity of the miRNA array sig-
nals, seven miRNAs that discriminated between BRCA and
sporadic basal cancers in the array were randomly chosen
for measurement using reverse transcriptase real-time PCR.
Differences between the two groups were validated for four
of the seven miRNAs (mir-198, −374b, −218, −149) real-
time PCR (p = 0.0015–0.0289) (Additional file 3: Figure S2),
yielding a specificity of 57 %. For the 4 validated miRNAs, a
moderate correlation was seen between data derived from
the array and from RT-PCR (Pearson r = 0.503–0.672, all
p < 0.05) (Additional file 4: Figure S3). There was a trend
for lower mir-190b expression in BRCA1 cancers, al-
though this was not statistically significant (p = 0.0914).
No difference in mir-590-3p expression was seen between
the two groups (p = 0.962). This may be due to reduced
accuracy of measurement in the array at low concentra-
tions, as reflected by the low concentrations for these 2
miRNAs (<2−6 relative to RNU6B) on RT-PCR. The con-
centration of mir-892a was below detection limit on RT-
PCR (Cp > 35 cycles).
Table 1 Grade independent basal phenotype miRNA signature in common with other studies [12, 13, 49, 50]
miRNA in common with other studies Unadjusted p value Adjusted p value Fold change Expression in basal vs. luminal
hsa-miR-149 [14, 16] 0.0246 0.2556 −2.21 Down
hsa-miR-29c [14–16, 50, 51] 0.0315 0.2838 −1.22 Down
hsa-miR-29c* [15, 16, 50] 0.0278 0.2679 −1.61 Down
hsa-miR-109b [14, 50] <0.0001 <0.0001* −11.77 Down
hsa-miR-125a-5p [14] 0.0203 0.2292 −1.13 Down
hsa-miR-136 [12] 0.0247 0.1120 −1.78 Down
hsa-miR-199a*:9.1 [12] 0.0138 0.0777 −1.47 Down
hsa-miR-342-3p [14–16] 0 < 0.0001 0.0024* −1.58 Down
hsa-miR-342-5p [12–16, 49] <0.0001 0.0001* −1.97 Down
hsa-miR-375 [15, 16, 50] 0.0005 0.0177 −3.56 Down
hsa-let-7c [12, 15] 0.0020 0.0232* −1.26 Down
hsa-let-7f [12] 0.0300 0.1284 −1.11 Down
hsa-let-7a [12] 0.0467 0.1669 −1.05 Down
hsa-miR-17 [15, 16, 50] <0.0001 0.0002* 1.74 Up
hsa-miR-17* [14–16, 50] 0.0004 0.0162* 1.30 Up
hsa-miR-18a [12–16, 32, 50, 52] <0.0001 <0.0001* 5.22 Up
hsa-miR-18b [14–16, 50] 0.0269 0.2676 1.89 Up
hsa-miR-19a [14–16, 50] 0.0006 0.0191* 3.37 Up
hsa-miR-19b [15, 16] 0.0005 0.0171* 1.90 Up
hsa-miR-93 [12, 13, 16] 0.0001 0.0032* 1.30 Up
hsa-miR-106a [12, 13, 50] <0.0001 0.0011* 1.87 Up
hsa-miR-106b [12, 13, 15, 50] 0.0151 0.0814 1.59 Up
hsa-miR-135b [12–16, 50] <0.0001 0.0017* 4.44 Up
hsa-miR-142-5p [12, 13] 0.0019 0.0229* 2.07 Up
hsa-miR-20a [15, 16] <0.0001 0.0001* 1.51 Up
hsa-miR-224 [14, 16] 0.0004 0.0162 4.75 Up
hsa-miR-455-5p [14] 0.0159 0.1986 2.08 Up
hsa-miR-505 [50] 0.0030 0.0741 2.83 Up
hsa-miR-519a [14] <0.0001 0.0007* 9.05 Up
hsa-miR-521 [14] <0.0001 <0.0001* 8.97 Up
hsa-miR-522 [14] <0.0001 0.0004* 10.79 Up
hsa-miR-9 [14] 0.0069 0.1260 4.60 Up
hsa-miR-9* [14, 16] 0.0322 0.2838 2.50 Up
hsa-miR-93 [15, 16] 0.0003 0.0142 1.32 Up
*significant p < 0.05 after adjustment for multiple tests
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Predicted targets of miRNA differentially expressed
between BRCA1 and sporadic basal cancers
The predicted targets of the top 32 miRNAs differentially
expressed between BRCA1 and basal cancers (excluding
mir-892, −190b and 590-3p) were sought via a union
search of miRBase and TargetScan. Predicted genes tar-
geted by 3 or more miRNAs were retained for a subse-
quent analysis. This resulted in a list of 1218 genes
predicted to be up (562) and down (656) regulated in
BRCA1 basal cancers by miRNAs (Additional file 1: Table
S4 and S5). Of these 1218 genes, there was overlap of 71
genes (5.8 %) between the two lists.
The subset of predicted target mRNAs in BRCA1 and
sporadic basal cancers, differentially expressed due to
miRNA and RISC mediated cleavage was then investi-
gated. Gene expression was compared between 14
BRCA1 basal and 10 non-BRCA1 basal cancers derived
from Waddell et al.’s cohort. In a three-dimensional plot
generated from an exploratory principle component ana-
lysis, the BRCA1 cancers formed a small cluster within a
larger cluster incorporating all basal cancers (Fig. 3).
Genes differentially expressed between BRCA1 and spor-
adic basal cancers were cross-matched with list of genes
predicted to be targeted by differentially expressed
miRNAs, to obtain a list of genes predicted to be reg-
ulated by RISC mediated cleavage (Additional file 1:
Table S6).
Immunohistochemical analysis of predicted miRNA
targets in BRCA1 and sporadic basal cancers
The protein expression of four genes predicted to be
down-regulated (cyclin D1, FOXP1, NRP1 and ERβ) and
two predicted to be up-regulated (FIH-1 and CD99) by
miRNA expression in BRCA1 vs. sporadic basal cancers
were assessed via immunohistochemical staining on
TMAs constructed from an cohort of 35 BRCA1 and 52
sporadic basal cancers. BRCA1 basal cancers, when
compared to sporadic basal cancers showed reduced
positivity for FOXP1 (6/20 [30 %] vs. 37/49 [76 %], p <
0.001), cyclin D1 (8/22 [36 %] vs. 30/46 [65 %], p =
0.025), NRP1 (2/20 [10 %] vs. 23/46 [50 %], p = 0.002)
and CD99 (17/20 [85 %] vs. 7/19 [37 %], p = 0.002)
(Table 3, Additional file 5: Figure S4). Differences in ex-
pression between the tumour groups were also signifi-
cant when their scores (out of 7) were compared using a
Mann-Whitney U test (all p ≤ 0.005). No differences in
FIH-1 and ERβ expression were seen between the two
groups (p > 0.05).
Fig. 2 Unsupervised hierarchical cluster analysis, all basal cancers and basal cell lines, over 100 classifying miRNAs (Pearson correlation,
average linkage)
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Immunohistochemistry for FOXP1, cyclin D1, NRP1
and CD99 was repeated on a second validation cohort
of 82 BRCA1 and 65 sporadic basal cancers. Statisti-
cally significant differences were confirmed for
FOXP1, cyclin D1 and NRP1 (Pearson chi square all
p < 0.001, Fig. 4 and Table 4). An opposite association
for CD99 was observed with sporadic basal cancers
showing increased expression compared to BRCA1
cancers (p = 0.024). Differences between the tumour
groups were also observed when their scores (out of 7)
were compared using a Mann-Whitney U test (all p <
0.001).
Using negative staining for 2 or more out of 3 stains
(FOXP1, cyclin D1 and NRP1) to predict germline
BRCA1 mutation resulted in a sensitivity of 92 % and a
specificity of 44 %. Assuming 1) the prevalence of
BRCA1 in the breast cancer population is 2 % [5]; 2)
15 % of breast cancers have a basal phenotype [1, 4];
and 3) 69 % of all BRCA1 cancers have a basal
phenotype [30], the positive predictive value (PPV) is
Table 2 miRNAs discriminating BRCA1 from sporadic basal cancers (fold change > 2.5, adjusted p < 0.05)
miRNA Adjusted p value Fold change Expression in BRCA1 vs. basal Cytoband Correlation with previous BRCA1 CGH findings
hsa-miR-892a 0.0002 −7.98 Up Xq27.3
hsa-miR-1247 0.0015 −6.26 Up 14q32.31
hsa-miR-129-3p 0.0001 −6.03 Up 11p11.2
hsa-miR-494 0.0014 −5.84 Up 14q31
hsa-miR-1273 0.0008 −5.43 Up 8q22.2 [53]
hsa-miR-198 0.0004 −5.34 Up 3q13.33 [54]
hsa-miR-30c-1* <0.0001 −4.51 Up 1p34.2
hsa-miR-1281 0.0001 −3.88 Up 22q13.2
hsa-miR-220b <0.0001 −3.76 Up 19p13.3
hsa-miR-566 <0.0001 −3.75 Up 3p21.31
hsa-miR-603 0.0003 −3.73 Up 10p12.1 [53, 55]
hsa-miR-675 0.0018 −3.53 Up 11p15.5
hsa-miR-637 0.0012 −3.31 Up 19p13.3
hsa-miR-576-3p 0.0014 −3.26 Up 4q25
hsa-miR-638 0.0366 −3.04 Up 19p13.2
hsa-miR-1826 <0.0001 −3.03 Up 16p11.2 [54]
hsa-miR-1268 0.0218 −2.96 Up 15q11.2 [53]
hsa-miR-1234 0.0076 −2.79 Up 8q24.3 [53, 56]
hsa-miR-1285 0.0428 −2.69 Up 7q21.2
hsa-miR-509-5p 0.0043 −2.53 Up Xq27.3
hsa-miR-374b 0.0026 7.00 Down Xq13.2 [53]
hsa-miR-590-3p 0.0101 5.25 Down 7q11.23
hsa-miR-218 0.0264 4.02 Down 4p15.31 [56]
hsa-miR-335* 0.0428 3.82 Down 7q32.2
hsa-miR-190b 0.0204 3.81 Down 1q21.3
hsa-miR-96 0.0405 3.48 Down 7q32.2
hsa-miR-454* 0.0405 3.21 Down 17q22
hsa-miR-576-5p 0.0218 3.03 Down 4q25
hsa-miR-340* 0.0111 3.01 Down 5q35.3 [53]
hsa-miR-29a* 0.0008 3.00 Down 7q32.3
hsa-miR-148b 0.0014 2.90 Down 17q13.13 [56]
hsa-miR-130b* 0.0076 2.89 Down 22q11.21
hsa-miR-149 0.0443 2.77 Down 17q37.3
hsa-miR-10a 0.0076 2.71 Down 17q21.32
hsa-miR-660 0.0428 2.56 Down Xp11.23
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Fig. 3 Three-dimensional PCA plot of gene expression array data for 14 BRCA1 and 10 non-BRCA1 basal cancers
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Table 3 miRNAs and expression of their predicted targets as assessed by immunohistochemistry (IPX) for the initial cohort of 35 BRCA1 and 52 sporadic basal cancers
miRNA miRNA expression















Positive IPX in sporadic,
n (%)




on IPX score out of 7
hsa-miR-509-5p Up 2.53 0.004 FOXP1 Down 6 (30 %) 37 (76 %) <0.001 <0.001
hsa-miR-1285 Up 2.68 0.042
hsa-miR-1826 Up 3.02 <0.001
hsa-miR-220b Up 3.76 <0.001
hsa-miR-1826 Up 3.02 <0.001 Cyclin D1 Down 8 (36 %) 30 (65 %) 0.025 0.004
hsa-miR-576-3p Up 3.26 0.001
hsa-miR-638 Up 3.04 0.036
hsa-miR-30c-1* Up 4.51 <0.001 NRP1 Down 2 (10 %) 23 (50 %) 0.002 0.003
hsa-miR-1285 Up 2.69 0.043
hsa-miR-129-3p Up 6.03 <0.001
hsa-miR-29a* Down 3.12 <0.001 CD99 Up 17 (85 %) 7 (37 %) 0.002 0.005
hsa-miR-130b* Down 2.95 <0.006
hsa-miR-132* Down 2.48 0.024











estimated to be 38 % and the negative predictive
value is estimated to be 94 %.
Discussion
Interest in breast cancers with basal features began with
Perou et al.’s paper based on cDNA arrays published in
2000 [31]. A number of studies assessing miRNA expres-
sion on basal cancers have been published since 2007
but none independent of grade. Thus, it has not been
possible to date to reconcile any changes with veracity
with regard to subtype or proliferation/differentiation,
known drivers of mRNA and miRNA expression [12–16].
The current study, comparing 27 grade 3 basal-like with
17 luminal grade 3 cancers, confirms there are a number
of miRNA differentially expressed between luminal and
basal cancers, independent of grade, some of which in-
cluding mir-17-92 cluster (mir-17, 17*, 18a, 19a/b, 20a
and 106a), have been linked to basal-like phenotype in
these previous studies [12, 14, 15, 32]. The expression of
this cluster appears to be influenced by DNA copy num-
ber [15], and may be involved in the oncogenesis of basal-
like cancers. These miRNAs promote tumour progression
Fig. 4 Negative immunoperoxidase staining for cyclin D1, FOXP1 and NRP1 in BRCA1 basal cancers (a, b and e). Positive staining in sporadic
basal cancers for cyclin D1, FOXP1 and NRP1 (b, d and f). Note positive nuclear staining in stromal cells and negative staining in tumour cells for
cyclin D1 (a) and FOXP1 (c). (x10, Haematoxylin counterstain)
Table 4 Expression of FOXP1, cyclin D1 and NRP1, as assessed by immunohistochemistry (IPX) for the second validation cohort of
82 BRCA1 and 65 sporadic basal cancers
Predicted target
gene
Positive IPX in BRCA1,
n (%)
Positive IPX in sporadic,
n (%)
p value (chi square) positive
or negative on IPX
p value (Mann-Whitney) on IPX
score out of 7
FOXP1 43 (52 %) 58 (94 %) <0.001 <0.001
Cyclin D1 47 (57 %) 50 (89 %) <0.001 <0.001
NRP1 33 (41 %) 42 (72 %) <0.001 <0.001
CD99 23 (28 %) 26 (47 %) 0.024 0.012
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via: reduced stiffness of the extracellular matrix due to re-
duced expression of PTEN (mir-18a) [32], facilitation of
cell migration and metastasis (mir-18b) [33], suppres-
sion of tumour suppressor genes ZBTB4 [34] and
Rb(mir-106b) [35]. Loss of miRNAs may also be impli-
cated in the activation of oncogenes, with loss of mir-375
and let-7a being implicated in epithelial-mesenchymal
transition in breast cancer cells [36]. Our findings suggest
these processes are specific to basal-like cancers, and are
independent of tumour differentiation as reflected by the
tumour grade.
Unsupervised clustering also suggests that basal-type
cancers show significant heterogeneity in miRNA ex-
pression. This is in keeping with previous studies by
Sotiriou et al. [37] and Kao et al. [38], who divided 26
basal cancers and 13 basal cell lines respectively into 2
subgroups, whereas Kreike et al. [39] divided 97 basal
cancers into 5 subgroups. In this study, at one end of
the spectrum, there is a subgroup composed entirely of
10 BRCA1 cancers, at the opposite end there is a cluster
entirely composed of 11 sporadic cancers, which has a
pattern of miRNA expression resembling in vitro basal
cell lines. Thus, these data support our findings that
BRCA1 cancers have a distinct miRNA signature and
form a distinct subgroup within the basal cancers, char-
acterised by the up-regulation of a number of miRNAs
involved in regulation of the MAPK/ERK pathway
(MPA3K2, MAP2K4, MAP4K4, PTPN2 [40], CHUK
[41], PDGFRA [42], ERBB4, JAK3 [43]), and 2) histone
modification (HDAC8, MYST2, MLL).
Of the six proteins that were investigated via immuno-
histochemistry, four (cyclin D1, FOXP1, NRP1 and
CD99) showed reduced expression in BRCA1 cancers in
the initial cohort with reduced expression for FOXP1,
cyclin D1 and NRP1 subsequently confirmed in the val-
idation cohort. Increased expression for CD99 in BRCA1
cancers was not reproduced in the validation cohort,
where reduced expression was observed. While there
were no accompanying changes in mRNA expression for
these proteins, it is known that only ~ 20 % of mRNA
targeted by miRNAs undergo RISC mediated cleavage.
Hence it is likely that these three genes are part of the
majority of genes that undergo translational silencing
without an associated reduction in mRNA expression
[21, 22].
Of these three genes, low cyclin D1 expression has been
previously demonstrated in BRCA1 cancers [24, 25]. Re-
duced cyclin D1 expression in BRCA1 basal cancers may,
in part, be due to the inhibition of translation mediated by
mir-576-3p, mir-1826 and mir-638. Conversely, increased
cyclin D1 expression in sporadic basal cancers may have
important biological implications. For instance, direct tar-
geting of cyclin D1 by NOTCH1 and 3 has been linked to
cell cycle progression in basal cancers [44]. In addition,
phosphorylation of BRCA1 by cyclin D1 has been shown
to interfere with DNA dependent activities of BRCA1
[45]. Expression of NRP1 in sporadic cancers may have
potentially important therapeutic applications, in view of
the development of anti-NRP monoclonal antibodies and
cell penetrating peptides [46].
Using negative staining for 2 or more out of 3 stains
(FOXP1, cyclin D1 and NRP1) to predict germline
BRCA1 mutation resulted in a positive predictive value
(PPV) of 38 % and a negative predictive value of 94 %.
While this PPV is relatively low due to the rarity of
BRCA1 mutations in the population, its value is likely to
improve in patients with a family history of breast can-
cer and/or early onset cancers. Nevertheless, our find-
ings suggest immunohistochemistry for FOXP1/NRP1/
cyclin D1 may be useful, in conjunction with family his-
tory, in selecting patients with basal cancers for BRCA1
screening.
Conclusion
In summary, our study demonstrates basal-like cancers
have a grade independent miRNA expression profile.
Furthermore miRNA driven differences in the expres-
sion of proteins by BRCA1 vs. sporadic basal cancers
may be detected via immunohistochemical staining of
paraffin embedded tissue. These findings may have im-
portant diagnostic implications, as immunohistochemical
assessment of basal cancers, in addition to the patient’s
family and clinical history, may potentially identify pa-
tients who may benefit from BRCA1 gene testing. Lastly,
there is evidence to suggest BRCA1 deficient cancers may
be sensitive to PARP inhibitors [47]. Hence stratification
of basal-like cancers, based on the “BRCA1-ness” of their
miRNA signature, generated from archival FFPE tissue,
may be highly relevant to clinical trials investigating tar-
geted therapies, such as PARP inhibitors [48]. Validation
of these findings in larger patient cohorts, however, will
be required to assess the diagnostic utility of such an
approach.
Additional files
Additional file 1: Table S1. Clinico-pathological characteristics of
tumour samples (all grade III) for miRNA analyses. Table S2. Layout of
samples across 6 Illumina miRNA Beadchips. Table S3. Antibodies used
for immunohistochemical staining of tissue microarrays. Table S4. Predicted
genes up regulated in BRCA1 basal cancers, targeted by 3 or more miRNAs.
Table S5. Predicted genes up regulated in sporadic basal cancers, targeted
by 3 or more miRNAs. Table S6. Subset of predicted target mRNAs regulated
by RISC mediated cleavage in BRCA1 and sporadic basal cancers.
Additional file 2: Figure S1. Correlation of control miRNA profiles
across beadchips. The probe intensities for control samples were correlated
across the 6 Illumina beadchips hybridised on 2 separate runs (Run 1: 1
beadchip with 11 samples, Run 2: 5 beadchips with 58 samples). Excellent
correlations for raw miRNA probe intensities were obtained between
control samples across the five beadchips hybridised on the same run
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(Run 2, Spearman r = 0.9631–0.9906, all p < 0.001) (Additional file 2:
Figure S1a). For control samples hybridised on different runs, a weaker
correlation was observed (Spearman r = 0.8139, p < 0.001) (Additional
file 2: Figure S1b). Occasional probes were observed to have a much
stronger signal in the smaller run 1 (4687786010_L) compared to run 2
(4726968002_E). A small improvement in the correlation between these
two samples was observed following quantile normalisation and log 2
transformation (Pearson r = 0.8538, p < 0.001) (Additional file 2: Figure
S1c). Additional file 2: Figure S1a. Scatterplot of raw miRNA probe
intensities from control samples across 2 beadchips hybridised on the
same run (Spearman r = 0.9906, p < 0.001); Additional file 2: Figure S1b.
Scatterplot of raw miRNA probe intensities from control samples hybridised
on separate runs (Spearman r = 0.8139, p < 0.001); Additional file 2: Figure
S1c. Scatterplot of probe intensities of control samples (from Additional file
2: Figure S1b), hybridised on separate runs following quantile normalisation
and log 2 transformation (Pearson r = 0.8538, p < 0.001).
Additional file 3: Figure S2. RT-PCR validation of mir-374b, mir-149,
mir-218 and mir-198 in discriminating between BRCA1 and sporadic basal
breast cancers (all p < 0.05). A trend was seen for mir-190b although this
was not statistically significant (p = 0.0914). No differences in the expression
of mir-590-3p were observed (p = 0.9623).
Additional file 4: Figure S3. Correlation between microarray and RT-PCR
(relative to RNU6B) measurements for mir-198 (r = 0.672, p = 0.0023), mir-149
(r = 0.567, p = 0.0344), mir-218 (r = 0.521, p = 0.0385) and mir-374b (r = 0.503,
p = 0.0335).
Additional file 5: Figure S4. Distribution of scores in BRCA1 and
sporadic basal type cancers for cyclin D1 (p = 0.004), FOXP1 (p < 0.001)
and NRP1 (p = 0.003).
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